Here is the design of a clinical trial:

Official Title: Clinical Trial on the Survival Advantage of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Included conditions:
- NSCLC

Study Armgroups:
- {'label': 'Kanglaite Injection + Chemotherapy', 'type': 'EXPERIMENTAL', 'description': 'Participants receive Kanglaite Injection PLUS first-line chemotherapy.', 'interventionNames': ['Drug: Kanglaite Injection+Chemotherapy']}
- {'label': 'Chemotherapy', 'type': 'ACTIVE_COMPARATOR', 'description': 'first-line chemotherapy.', 'interventionNames': ['Drug: Chemotherapy']}

Interventions:
- {'type': 'DRUG', 'name': 'Kanglaite Injection+Chemotherapy', 'description': "Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.", 'armGroupLabels': ['Kanglaite Injection + Chemotherapy']}
- {'type': 'DRUG', 'name': 'Chemotherapy', 'description': "Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.", 'armGroupLabels': ['Chemotherapy']}

Primary Outcomes:
- {'measure': 'Progression Free Survival(PFS)', 'description': 'Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)', 'timeFrame': 'Randomization until disease progression, death, or 12 months after randomized enrollment, whichever occurs first.'}

Please estimate the sample size based on the assumption: 
95% confidence level, 80% power, and 20% drop-out rate.
Sample size
        The sample size was calculated based on the primary study outcome. The previously reported PFS of maintenance pemetrexed plus best supportive care for NSCLC was 4.3âmonths (95% confidence interval [CI]: 4.1â4.7), whereas the PFS for placebo plus best supportive care was 2.6âmonths (95% CI: 1.7â2.8) [42]. Some studies showed that KLTi in combination with chemotherapy improved clinical efficacy compared with chemotherapy alone in patients with NSCLC [30â33]. Therefore, we predict that the PFS in the treated group will be 2.1âmonths longer than that in the control group. A sample size calculation using PASS software (Version 11.0, NCSS, LLC. Kaysville, UT, USA) estimates that 167 participants would be required in the treatment and control groups (i.e., total of Nâ=â334), with 95% confidence level, 80% power, and 20% drop-out rate.